HAYWARD, Calif., Dec. 1, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera’s President and Chief Executive Officer, will present at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference in San Francisco, CA on Tuesday, December 7, 2010 at approximately 9:30 am Pacific Time.
Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference Presentation | |
Date/Time: Tuesday, December 7, at 9:30 am Pacific Time | |
Location: The Nikko Hotel | |
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera’s Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc.
